OxoN Medica

OxoN Medica was a biopharmaceutical company based in South San Francisco, California, focused on the development of multifunctional small molecule drugs for diseases associated with endothelial dysfunction. The company's research centered on nitric oxide (NO) signaling pathways, oxidative stress, and endothelin regulation to treat conditions such as hypertension, diabetic complications, and glaucoma. Led by a team of prominent scientists and advisors, including Nobel laureate Ferid Murad and pharmacokineticist Leslie Benet, OxoN Medica aimed to create therapies that could restore vascular health. However, the company's lead program, OX-008, was discontinued, and the firm is no longer active in the biotechnology sector.